Corneal Crosslinking for Keratoconus

This trial explores a treatment called corneal crosslinking (CXL) to determine if it can halt the progression of eye conditions like keratoconus, which thins and misshapes the cornea, causing blurry vision. CXL involves applying vitamin B2 eye drops and using UV light to strengthen the cornea. The trial is open to individuals 8 years or older with Down syndrome and a diagnosed corneal condition, such as keratoconus. Participants must attend several office visits for eye tests over six months. As a Phase 3 trial, this represents the final step before FDA approval, offering a chance to contribute to a potentially groundbreaking treatment.

The trial information does not specify whether you need to stop taking your current medications. However, you must be able to remove contact lenses for a certain period before exams.

Research has shown that Epi-ON corneal collagen crosslinking (CXL) is generally safe and well-tolerated. In studies, this treatment caused fewer side effects compared to other methods. Epi-ON CXL helps halt keratoconus, a condition where the cornea becomes thin and misshapen. By keeping the eye's surface intact during the procedure, the risk of infection decreases, and recovery speeds up, enhancing patient comfort. Overall, the treatment is considered safe, making it a promising option for those considering it.¹²³⁴⁵

Epi-ON Corneal Collagen Crosslinking is unique because it offers a gentler approach to treating keratoconus that doesn't require removing the eye's outer layer, unlike the standard Epi-OFF procedure. This non-invasive method reduces discomfort and speeds up recovery time, making it more convenient for patients. Researchers are excited because it maintains the integrity of the corneal epithelium, potentially lowering the risk of infection and other complications associated with traditional crosslinking treatments.

Research has shown that Epi-On Corneal Collagen Crosslinking (CXL) effectively halts the progression of keratoconus. Keratoconus causes the cornea, the clear front part of the eye, to become thin and misshapen. Studies have found that this treatment can improve vision and flatten the cornea, reducing blurred vision. In previous research, none of the patients who underwent Epi-On CXL experienced further corneal issues. This suggests that Epi-On CXL is both safe and effective in preventing the condition from worsening. While other treatments exist, Epi-On CXL stands out because it works without removing the outer layer of the cornea, making it safer and more comfortable for patients.¹²³⁶⁷